MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
2.740
0.000
0.00%
Opening 11:13 03/28 EDT
OPEN
2.740
PREV CLOSE
2.740
HIGH
2.810
LOW
2.670
VOLUME
271.09K
TURNOVER
0
52 WEEK HIGH
3.220
52 WEEK LOW
0.5000
MARKET CAP
411.90M
P/E (TTM)
-3.4233
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at HRTX last week (0318-0322)?
Weekly Report · 3d ago
Heron Therapeutics Announces New Principal Accounting Officer
TipRanks · 6d ago
Weekly Report: what happened at HRTX last week (0311-0315)?
Weekly Report · 03/18 11:07
Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?
Heron Therapeutics Inc (NASDAQ:HRTX) reported a fourth-quarter 2023 EPS of $0.07. Sales increased 14% Y/Y to $34.23 million. Needham maintains its Buy rating on the company's stock.
Benzinga · 03/13 18:41
12 Health Care Stocks Moving In Wednesday's Intraday Session
Heron Therapeutics shares rose 35.4% to $3.19 during Wednesday's regular session. The company's, Q4 earnings came out yesterday. Trxade Health (NASDAQ:MEDS) shares fell 22.6% during the session. NuCana stock rose 34.32% and Cardiff Oncology shares increased by 27.9%.
Benzinga · 03/13 17:31
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Clover Health Investments, Corp. Shares jumped 11.2% to $0.8537 on Wednesday. The company reported better-than-expected fourth-quarter revenue results. Gaxos.ai shares jumped 128.9% after the company acquired rights to use certain AI-enabled technology from Ultiself. Veritone, Inc. And The Beauty Health Company also gained.
Benzinga · 03/13 17:18
HRTX, LUNA and ARQ among mid-day movers
On the Move HRTX, LUNA and ARQ among mid-day movers. Gaxos.AI and MicroCloud Hologram are among the Gainers. 1847 Holdings and Luna Innovations were among the losers in SA's list of companies.
Seeking Alpha · 03/13 17:18
Heron Therapeutics Soars After 4Q Earnings Beat
Heron Therapeutics' stock was up 27% after its fourth-quarter earnings beat expectations. Shares of the San Diego-based biotechnology company rose to $3.01 in morning trading. The stock is up more than 20% over the past 12 months. Heron narrowed its losses and beat expectations in the fourth quarter.
Dow Jones · 03/13 15:00
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF, HTX-019, and HTX-034. HTX- ZYNRELEF is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting in adults. HTX-034 is a product candidate for postoperative pain management.

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.